Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

Wilson Gonsalves, Kelly Godby, Shaji K Kumar, Luciano J. Costa

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

In the era of novel biological agents, multiple myeloma (MM) is often approached as a chronic condition. While survival continues to improve, population-level data indicate that early mortality remains a substantial barrier to advances in MM outcomes. Here we provide "do's and don'ts" management recommendations that may minimize the risk of early mortality and ensure that patients have the opportunity to benefit from the long term impact of new effective MM agents. Such recommendations encompass the early introduction of novel agents even in the presence of comorbidities and advanced age and aggressive management of MM-related complications. Am. J. Hematol. 91:101-108, 2016.

Original languageEnglish (US)
Pages (from-to)101-108
Number of pages8
JournalAmerican Journal of Hematology
Volume91
Issue number1
DOIs
StatePublished - Jan 1 2016

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

  • Cite this